This week, we will discuss sparsentan again, but this time in FSGS. This is the largest FSGS trial ever. Will endothelin antagonists crack the sclerotic FSGS segment?
The ENAKT-LKD Visual Abstract
Another sterlling visual abstract from Milagros Flores